AGI-14100
AGI-14100 is a metabolically stable and orally available mIDH1 inhibitor (IC50=6 nM) . The pharmacochemical optimization of AGI-14100 is aimed at eliminating hPXR activation, resulting in the final drug candidate AG-120. AG-120 can be used in the study of cancers carrying IDH1 mutations. The discovery and development of AGI-14100 can be used for further studies of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitors[1].
Product Specifications
CAS Number
[1448346-43-7]
UNSPSC
12352005
Target
Isocitrate Dehydrogenase (IDH)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/agi-14100.html
Solubility
10 mM in DMSO
Smiles
O=C([C@@H](N1C2=NC=CC(C#N)=C2)CCC1=O)N([C@@H](C3=CC=CC=C3Cl)C(NC4CC(C4)(F)F)=O)C5=CC(F)=CC(F)=C5
Molecular Formula
C29H22ClF4N5O3
Molecular Weight
599.96
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Recombinant Mycobacterium ulcerans Riboflavin biosynthesis protein ribBA (ribBA)
Recombinant Mycobacterium ulcerans Riboflavin biosynthesis protein ribBA (ribBA)
Recombinant Mycobacterium ulcerans Riboflavin biosynthesis protein ribBA (ribBA)
Recombinant Mycobacterium ulcerans Riboflavin biosynthesis protein ribBA (ribBA)
Recombinant Mycobacterium ulcerans Riboflavin biosynthesis protein ribBA (ribBA)